Zymeworks Inc. (NasdaqGS: ZYME)
Health Care · Biotechnology · US
$29.40
+2.19% today · +97.5% 1Y
Zymeworks Inc. (NasdaqGS: ZYME) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.04B and employs 231 people.
Over the last twelve months the share price has gained 97.5%, trading between 13.48 and 29.75.
Tweenvest scores Zymeworks Inc. across four factors: quality 29/100, value 69/100, growth 57/100. Its strongest factor is value.
ZYME price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.04B
- Revenue (TTM)
- $37.13M
- P/E
- —
- EPS
- -2.01
- Dividend yield
- —
- Beta (5Y)
- 1.15
- 52-week high
- $29.75
- 52-week low
- $13.48
- Avg volume (3M)
- —
- Shares outstanding
- 70.96M
- Employees
- 231
- Next earnings
- —
About Zymeworks Inc.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
- ISIN
- US98985Y1082
- Founded
- 2003
- Listed since
- Apr 28, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.28 | +0.29% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.52 | +0.15% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.77 | +0.70% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $551.83 | +0.77% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.53 | +0.85% |
| argenx SEENXTBR: ARGX | $63.06B | €878.20 | +1.62% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $153.20 | +10.30% |
Figures last refreshed Aug 18, 2026.